TOMBERLI, ALESSIA
 Distribuzione geografica
Continente #
NA - Nord America 1.015
EU - Europa 834
AS - Asia 251
OC - Oceania 8
AF - Africa 4
SA - Sud America 1
Totale 2.113
Nazione #
US - Stati Uniti d'America 1.013
RU - Federazione Russa 401
IT - Italia 143
IE - Irlanda 79
PL - Polonia 76
SE - Svezia 68
SG - Singapore 66
HK - Hong Kong 59
CN - Cina 49
IN - India 28
JO - Giordania 22
DE - Germania 16
CH - Svizzera 14
ID - Indonesia 11
FI - Finlandia 9
VN - Vietnam 9
AU - Australia 8
GB - Regno Unito 8
NL - Olanda 6
RS - Serbia 5
PH - Filippine 4
CI - Costa d'Avorio 3
CA - Canada 2
ES - Italia 2
KR - Corea 2
UA - Ucraina 2
BE - Belgio 1
CL - Cile 1
FR - Francia 1
GR - Grecia 1
JP - Giappone 1
LT - Lituania 1
MA - Marocco 1
PT - Portogallo 1
Totale 2.113
Città #
Santa Clara 395
Dublin 79
Chandler 77
Warsaw 73
Fairfield 70
Singapore 57
Ashburn 53
Hong Kong 44
Florence 36
Moscow 36
Seattle 32
Cambridge 29
Houston 29
Woodbridge 29
New York 26
Wilmington 26
Lawrence 24
Mumbai 23
Altamura 21
Buffalo 15
Princeton 15
Beijing 14
Bern 14
Shanghai 14
Milan 12
Boston 11
Jakarta 11
Munich 10
Naples 10
Prato 9
Dong Ket 8
Melbourne 8
Helsinki 7
Kent 7
Medford 7
Ann Arbor 6
Boardman 6
San Diego 6
Belgrade 5
Abidjan 3
Hillsboro 3
Quezon City 3
Siena 3
Andover 2
Anghiari 2
Cervia 2
Chennai 2
Duncan 2
Falls Church 2
Gubbio 2
Lappeenranta 2
Lecce 2
Livorno 2
Los Angeles 2
Norwalk 2
Pontedera 2
Salerno 2
Seoul 2
Torremolinos 2
Vellore 2
Vicenza 2
Wandsworth 2
Yubileyny 2
Amsterdam 1
Anguillara Sabazia 1
Athens 1
Bari 1
Breendonk 1
Bruino 1
Changsha 1
Clifton 1
Ercolano 1
Frankfurt am Main 1
Genova 1
Grafing 1
Hanoi 1
Jinhua 1
Kilburn 1
London 1
Mem Martins 1
Nanjing 1
Newark 1
Ottawa 1
Palermo 1
Pavia 1
Prescot 1
Pune 1
Putian 1
Rome 1
San Miniato Basso 1
Santa Maria 1
Santiago 1
Sapporo 1
Scuola 1
Sestri Levante 1
Southwark 1
Staranzano 1
Tavarnuzze 1
Toronto 1
Washington 1
Totale 1.443
Nome #
Defining the diagnostic effectiveness of genes for inclusion in panels: the experience of two decades of genetic testing for hypertrophic cardiomyopathy at a single center 190
Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events 140
Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy 120
Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy 114
Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): Prospective evaluation at a tertiary referral centre 109
Doctor-patient care relationship in genetic cardiomyopathies: An exploratory study on clinical consultations 108
Comprehensive Risk Management in Arrhythmogenic Cardiomyopathy Associated With Autosomal Dominant Carvajal Syndrome 108
Myocardial blood flow in patients with hypertrophic cardiomyopathy receiving perindopril (CARAPaCE): a pilot study 107
Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy 104
Red flags for the diagnosis of cardiac amyloidosis: Simple suggestions to raise suspicion and achieve earlier diagnosis 96
Targeted Medical Therapies for Hypertrophic Cardiomyopathy 95
Efficacy and safety of dysopiramide in patients with obstructive hypertrophic cardiomyopathy 91
Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy 79
Prognostic value of cardiopulmonary exercise testing in patients with transthyretin cardiac amyloidosis 70
Incidence of stroke in patients with hypertrophic cardiomyopathy in stable sinus rhythm during long-term monitoring 70
Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis 70
Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions 69
Clinical course and outcome of pregnancy in patients with hypertrophic cardiomyopathy 65
Prevalence of anxiety and depression symptoms in a sample of outpatients with ATTR cardiac amyloidosis 62
Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center 61
Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy 61
Sex-related differences in clinical presentation and all-cause mortality in patients with cardiac transthyretin amyloidosis and light chain amyloidosis 60
Arrhythmic Burden in Cardiac Amyloidosis: What We Know and What We Do Not 59
Impact of Pregnancy on the Natural History of Women with Hypertrophic Cardiomyopathy 45
Totale 2.153
Categoria #
all - tutte 8.038
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.038


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202070 0 0 0 0 0 0 14 15 15 8 18 0
2020/2021206 14 4 10 29 10 11 20 14 21 45 16 12
2021/2022122 5 1 7 3 4 15 4 4 17 10 25 27
2022/2023399 27 85 18 24 26 57 57 22 42 10 13 18
2023/2024255 8 23 24 11 14 41 19 61 8 24 14 8
2024/20251.023 60 135 78 225 357 156 12 0 0 0 0 0
Totale 2.153